255 related articles for article (PubMed ID: 19629003)
1. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor.
Mroczko B; Lukaszewicz-Zajac M; Wereszczynska-Siemiatkowska U; Groblewska M; Gryko M; Kedra B; Jurkowska G; Szmitkowski M
Pancreas; 2009 Aug; 38(6):613-8. PubMed ID: 19629003
[TBL] [Abstract][Full Text] [Related]
2. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
3. Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.
Waas ET; Wobbes T; Ruers T; Lomme RM; Hendriks T
Eur J Surg Oncol; 2006 Sep; 32(7):756-63. PubMed ID: 16650961
[TBL] [Abstract][Full Text] [Related]
4. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9.
Koopmann J; Rosenzweig CN; Zhang Z; Canto MI; Brown DA; Hunter M; Yeo C; Chan DW; Breit SN; Goggins M
Clin Cancer Res; 2006 Jan; 12(2):442-6. PubMed ID: 16428484
[TBL] [Abstract][Full Text] [Related]
5. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic value of the measurement of matrix metalloproteinase 9 (MMP-9), squamous cell cancer antigen (SCC) and carcinoembryonic antigen (CEA) in the sera of esophageal cancer patients.
Mroczko B; Kozłowski M; Groblewska M; Łukaszewicz M; Nikliński J; Jelski W; Laudański J; Chyczewski L; Szmitkowski M
Clin Chim Acta; 2008 Mar; 389(1-2):61-6. PubMed ID: 18155162
[TBL] [Abstract][Full Text] [Related]
7. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
8. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
10. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
11. [Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance].
Hu XX; Li L; Li DR; Zhang W; Cheng XQ; Zhang JQ; Tang BJ
Ai Zheng; 2004 Oct; 23(10):1194-8. PubMed ID: 15473934
[TBL] [Abstract][Full Text] [Related]
12. [Expression of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases in the hepatocellular carcinomas].
Wei QY; Wu YQ; Fan SQ
Hunan Yi Ke Da Xue Xue Bao; 2003 Jun; 28(3):212-6. PubMed ID: 14653069
[TBL] [Abstract][Full Text] [Related]
13. Significant relationship of matrix metalloproteinase 9 with nuclear grade and prognostic impact of tissue inhibitor of metalloproteinase 2 for incidental clear cell renal cell carcinoma.
Kawata N; Nagane Y; Hirakata H; Ichinose T; Okada Y; Yamaguchi K; Takahashi S
Urology; 2007 Jun; 69(6):1049-53. PubMed ID: 17572184
[TBL] [Abstract][Full Text] [Related]
14. Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure.
George J; Patal S; Wexler D; Roth A; Sheps D; Keren G
Am Heart J; 2005 Sep; 150(3):484-7. PubMed ID: 16169329
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and malignant ovarian tumours.
Määtta M; Talvensaari-Mattila A; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2007; 27(4C):2753-8. PubMed ID: 17695443
[TBL] [Abstract][Full Text] [Related]
16. [Assay of matrix metalloproteinase levels and their endogenous inhibitors in patients with laryngeal carcinoma].
Klisho EV; Savenkova OV; Kondakova IV; Perel'muter VM; Choĭnzonov EL; Shishkin DA
Vopr Onkol; 2007; 53(1):26-31. PubMed ID: 17649730
[TBL] [Abstract][Full Text] [Related]
17. High serum TIMP-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract][Full Text] [Related]
18. Serum tissue inhibitors of metalloproteinase-1 and -2 in patients with non-small cell lung cancer.
Suemitsu R; Yoshino I; Tomiyasu M; Fukuyama S; Okamoto T; Maehara Y
Surg Today; 2004; 34(11):896-901. PubMed ID: 15526122
[TBL] [Abstract][Full Text] [Related]
19. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Nikkola J; Vihinen P; Vuoristo MS; Kellokumpu-Lehtinen P; Kähäri VM; Pyrhönen S
Clin Cancer Res; 2005 Jul; 11(14):5158-66. PubMed ID: 16033831
[TBL] [Abstract][Full Text] [Related]
20. Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer.
Malaguarnera M; Cristaldi E; Cammalleri L; Colonna V; Lipari H; Capici A; Cavallaro A; Beretta M; Alessandria I; Luca S; Motta M
Arch Gerontol Geriatr; 2009; 48(2):213-7. PubMed ID: 18329114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
